



ASX Announcement
4 November 2022

Statement pursuant to Listing Rule 4.7C.3

OptiScan Imaging Limited (ASX: OIL) ('the Company' or 'OptiScan') advises that in accordance with ASX Listing Rule 4.7C.3, and as noted in Item 6 of the Company's September 2022 Appendix 4C, lodged by the Company on 31 October 2022, payments made to related parties and their associates during the quarter ended 30 September 2022 were \$215,000. These amounts related to Directors fees and superannuation payments made during the quarter ended 30 September 2022.

- ends -

This announcement has been authorised for release by the Board of OIL.

For investor queries, please contact:

Prof Camile Farah

CEO & Managing Director – OptiScan Imaging Limited

E: cfarah@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the sub-cellular level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

Phone (61 3) 9538 3333

Website www.optiscan.com

16 Miles Street, Mulgrave VIC 3170 Australia